



REGENX BIOSCIENCES HIGHLIGHTS PROGRESS USING NAV TECHNOLOGY TO PREVENT PANDEMIC INFLUENZA

*Company's **NAV rAAV9 Vectors** Delivering Antibodies via Intranasal Administration Show Broad Protection to Pandemic Flu Strains in Animal Models*

WASHINGTON, DC May 29, 2013 – REGENX Biosciences, LLC announces the publication of exciting new data presenting novel methods for non-invasive delivery of prophylactic treatment against pandemic influenza using **NAVTM** rAAV9 vectors. The research was led by REGENX Scientific Founder Dr. James M. Wilson, MD, PhD and his team at the University of Pennsylvania.

“Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza”, [published online](#) by *Science Translational Medicine* on May 29, 2013, reported that single doses of **NAV** rAAV9 expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gave the animals complete protection and substantial reductions in flu replication when exposed to lethal strains of flu viruses such as H1N1 and H5N1. These strains are associated with the infamous 1918, 2009 and “bird-flu” pandemics.

“This approach underscores the broad application of **NAV** technology as an important gene delivery platform.” said Ken Mills, President and CEO, REGENX Biosciences. “This novel demonstration, by Dr. Wilson and his colleagues, opens the door to a safe, durable method for delivery of antibodies for preventing flu and other infections. This application also demonstrates features that should overcome concerns about the distribution, administration and cost of antibody-based therapies in many parts of the world. Further development of this application of the **NAV** platform is merited and we look forward to continuing the support of this work as it addresses important public health threats.”

For more information about this gene therapy, go to:

http://www.uphs.upenn.edu/news/News_Releases/2013/05/wilson/

About REGENX Biosciences

REGENX Biosciences is leading the effort to translate promising gene delivery applications into a pipeline of next generation personalized therapies for a range of severe diseases with serious unmet

needs. We believe that the **NAV** technology to which we have exclusive rights represents the potential promise of curing the root cause of disease rather than the symptoms, and we are committed to establishing best in class standards for our **NAV** vectors. Our intent is to initially develop treatments for a number of rare, genetic diseases including hypercholesterolemias, the mucopolysaccharidoses, and retinitis pigmentosa and ensure continuing access for our **NAV** technology through innovative partnerships, license opportunities and the expansion of our growing team of global collaborators. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its **NAV** technology and related applications. Visit www.REGENXbio.com

###

Contact:
REGENX Biosciences
Vit Vasista, 202-785-7438
vvasista@regenxbio.com